Aldeyra Therapeutics, Inc. , a biotechnology company focused on the development of products to treat diseases related to free aldehydes, today announced that it has entered into a definitive purchase agreement to raise approximately $7.79 million in a private placement of common stock and warrants . Aldeyra plans to use the proceeds for its upcoming Phase 2 clinical trials in Sjogren-Larsson Syndrome and noninfectious anterior uveitis, working capital, and general corporate purposes.